Abstract
Background/Aims: The SARS-CoV-2 pandemic disproportionately impacted communities with lower access to health care in the United States, particularly before vaccines were widely available. These same communities are often underrepresented in clinical trials. Efforts to ensure equitable enrollment of participants in trials related to treatment and prevention of Covid-19 can raise concerns about exploitation if communities with lower access to health care are targeted for recruitment. Methods: To enhance equity while avoiding exploitation, our site developed and implemented a three-part recruitment strategy for pediatric Covid-19 vaccine studies. First, we publicized a registry for potentially interested participants. Next, we applied public health community and social vulnerability indices to categorize the residence of families who had signed up for the registry into three levels to reflect the relative impact of the pandemic on their community: high, medium, and low. Finally, we preferentially offered study participation to interested families living in areas categorized by these indices as having high impact of the Covid-19 pandemic on their community. Results: This approach allowed us to meet goals for study recruitment based on public health metrics related to disease burden, which contributed to a racially diverse study population that mirrored the surrounding community demographics. While this three-part recruitment strategy improved representation of minoritized groups from areas heavily impacted by the Covid-19 pandemic, important limitations were identified that would benefit from further study. Conclusion: Future use of this approach to enhance equitable access to research while avoiding exploitation should test different methods to build trust and communicate with underserved communities more effectively.
Original language | English (US) |
---|---|
Pages (from-to) | 390-396 |
Number of pages | 7 |
Journal | Clinical Trials |
Volume | 21 |
Issue number | 3 |
DOIs | |
State | Published - Jun 2024 |
Funding
The authors would like to thank Laura Fearn, Sarah Bertalsky, and Haley Widel for major contributions to recruitment and retention to the study. They also thank the families and children who registered interest in participating in a vaccine trial at a time when safety and efficacy in children were uncertain. The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: REDCap access was provided through the Northwestern University Clinical and Translational Sciences Institute (NUCATS). NUCATS is funded in part by a Clinical and Translational Science Award (CTSA) grant from the National Institutes of Health (NIH), UL1TR001422. The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: REDCap access was provided through the Northwestern University Clinical and Translational Sciences Institute (NUCATS). NUCATS is funded in part by a Clinical and Translational Science Award (CTSA) grant from the National Institutes of Health (NIH), UL1TR001422.
Keywords
- Trial equity
- underrepresented populations
- vulnerability index
ASJC Scopus subject areas
- Pharmacology